| INDICATIONS FOR EMERGENCY METHODS
 (1) Condom breakage or barrier method dislodged or torn during intercourse
 (2) Refusal of a partner to use protection
 (3) Exposure to possible teratogen, such as live vaccine, cytotoxic 
          drug, etc.
 (4) Forced sexual contact
 (5) Missed contraceptive pills: It is theoretically riskier when missed 
          at the beginning of a cycle and emergency contraception should be considered. 
          Even though the risk is extremely low at the end of the menstrual cycle, 
          a woman who has been raped or wants to avoid pregnancy for other reasons 
          may want to employ emergency contraception. This is a legitimate use 
          of the technique.
 The probability of conception when emergency 
          contraception should be considered is often unclear or misunderstood. 
          the average fertile period for a woman lasts only six days per menstrual 
          cycle and ends the day she ovulates. Unprotected sex three days before 
          ovulation results in an estimated 15 percent pregnancy rate; one or 
          two days before ovulation, about 12 percent. Sperm can survive in the 
          female up to five days and the mature egg may be fertilized over a 24-hour 
          period. The time period from ovulation to implantation is about seven 
          days.
 
 | 
    
      | RECOMMENDED 
        METHODS (1) Combined Oral Contraceptives: Uses estrogen-progestin combinations 
        (ethinyl estradiol and norgestrel/levonorgestrel) - also known as the 
        Yuzpe regimen after Albert Yuzpe, whose research on high-dose estrogen 
        regimens led to the current treatment protocols. The efficacy of combined 
        regimens that contain a progestin other than norgestrel/levonorgestrel 
        has not been studied.
 (2) The progestin-only minipill (levonorgestrel).
 (3) The Copper-T 380 intrauterine device (IUD).
 (4) Antiprogestins - Low doses of antiprogestin synthetic steroid RU 486 
        (mifepristone, Mifeprex) have been shown to be equally or more effective 
        than existing oral regimens for postcoital contraception. However, these 
        products are not readily available.
 | 
    
      | Combined Oral Contraceptives
 The FDA has reviewed the data on the Yuzpe regimen and concluded that 
          it is safe and effective. The American College of Obstetricians and 
          Gynecologists also reviewed the date and made a special recommendation 
          to its members that this regimen is underutilized and should be made 
          more widely available to patients seeking reproductive health care.
 Treatment: The regimen consists of 2 doses of ethinyl estradiol (100 ug) and 
          levonorgestrel (0.5 mg). The first dose should be taken within 72 hours 
          of unprotected intercourse and the second 12 hours after the first dose 
          (see Table). It is equally effective whether initiated early or late 
          within the 72-hour window. However, consider the timing of the second 
          dose when administering the first. For example, a first dose at 3 in 
          the afternoon will mean a second dose at 3 in the morning.
 The appropriate number of pills may be used 
          from different trade name birth control pill packages. Recently, a prepackaged, 
          dedicated product consisting of 4 pills (PREVEN) has beenn developed.
 If 100 women have unprotected intercourse 
          during the second and third week of their cycle, the probability is 
          that eight will become pregnant. If the Yuzpe method is used, only two 
          women will become pregnant (a 75% reduction).
 Side effects: Mainly gastrointestinal: nausea 50%, vomiting 20%. Taking the pills 
          with meals may reduce the risk of nausea, however, theoretically, this 
          may lower plasma hormonal levels and reduce contraceptive efficacy.
 Less common side effects are heavy menses 
          and mastalgia. Withdrawal bleeding occurs within three weeks of treatment. 
          Thirty-eight percent bleed before their menstrual period is due. About 
          8% may be 4 or more days late.
 Contraindications: Other than confirmed pregnancy, there are no absolute contraindications 
          to the emergency use of oral contraceptive combinations. Studies have 
          shown no evidence of harm to the developing fetus. Relative contraindications 
          include migraine with marked neurologic symptoms and preexisting venous 
          thromboembolic disease. Thrombotic episodes have been reported following 
          use of this regimen. Although it is not clear where these events were 
          actually related to hormone use, in these patients use of a progestin-only 
          pill or emergency IUD insertion is recommended. If the timing of exposure 
          makes the risk of pregnancy very slight, the safest course may be to 
          do nothing at all.
 In England, where emergency contraception 
          has been used in over 4 million cases in 13 years, no statistically 
          significant increase in the rate of deep venous thrombosis has occurred.
 Mechanism of action: Prevention 
          or delaying of ovulation may be the primary mechanism of drug action. 
          These hormones will not dislodge an implanted embryo. This is important 
          to convey to patients because it has obvious significance to anyone 
          whose religious beliefs prohibit interference with reproduction once 
          fertilization has taken place. Those who remain fearful about hormonal 
          side effects may prefer IUD insertion, or depending upon their likelihood 
          of pregnancy, no treatment at all.
 Patients have not be shown to become dependent 
          on this means of contraception. Also, the nausea associated with high 
          dosages is significant enough to make them think twice about requesting 
          this intervention on a regular basis.
 
          
            | Agents Used 
                for Emergency ContraceptionOvral (white), Femenal
 Norgestrel 0.50 + ethinyl 
                estradiol 50 ug
 Number of pills: 2
 
 LoOvral (white)
 Norgestrel 0.30 + ethinyl estradiol 30 ug
 Number of pills: 4
 
 Levlen (light orange), Nordette (light orange), 
                Levora (white), Microgynon 30, Nordette, Rigevidon 21+7 (seven containing lactose)
 Levonorgestrel 0.15 mg + ethinyl estradiol 30 ug
 Number of pills: 4
 
 Alese (pink)
 Levonorgestrel 0.1 mg + ethinyl estradiol 20 ug
 Number of pills: 5
 
 Trilevlen (yellow), Triphasil (yellow), Tiivora 
                (pink)
 Levonorgestrel 0.1 mg + ethinyl estradiol 30 ug
 Number of pills: 4
 
 Orvette (yellow)
 Norgestrel 0.075
 Number of pills: 20
 Dedicated ProductsPreven: Per dose: 2 blue pills, 100 ug of ethinyl estradiol, 0.50 mg levonorgestrel.
 Plan B: Per dose: 1 white pill, no ethinyl estradiol, 0.75 mg levonorgestrel.
 
 No of doses: 2 (two)
 Timing of administration: First dose within 72 hours of unprotected 
                intercourse; second dose 12 hours later. The patient may wish 
                to time her first dose as not to wake up during the night to take 
                the second dose. Norgestrel contains two isomers, only one of 
                which (levonorgestrel) is bioactive. Thus, 0.05 mg norgestrel 
                is equivalent to 0.25 mg levonorgestrel.
 (Red Brands: Philippine 
                Oral Contraceptives)
 |  
 | 
    
      | Management of Gastrointestinal Side Effects of Emergency Contraceptive 
          MedicationNonprescription Drugs
 Drug: 
          Meclizine hydrochloride
 Dose:1-2 (25mg) tablets
 Timing: 1 hr before first ECP dose; repeat if needed in 24 hr.
 
 Drug: Diphenhydramine Hcl
 Dose: 1-2 (25mg) tablets
 Timing: 1 hr before first ECP dose; repeat as needed q 4-6 hr.
 
 Drug: Dimenhydrinate
 Dose: 1-2 (50mg) tablets or 4-8 tsps
 Timing: 30 mins to 1 hr before 1st ECP dose; then q 4-6 hrs prn.
 
 Drug: Cyclizine Hcl
 Dose: 1 (50mg) tablet
 Timing: 30 mins before 1st ECP dose; then repeat q 4-6 hrs prn.
 
 Prescription Drugs
 Drug: 
          Meclizine Hcl
 Dose: 1-2 (25mg) tablets
 Timing: 1 hr before 1st ECP dose; repeat prn in 24 hrs.
 
 Drug: Trimethobenzamide HCL
 Dose: 1 (250 mg) tablet  or 200mg suppository
 Timing: 1 hr before first ECP dose; then prn q 6-8 hrs.
 
 Drug: Promethazine Hcl
 Dose: 1 (25mg) tablet or suppository
 Timing: 30 mins to 1 hr before 1st ECP dose; then prn q 8-12 hrs.
 | 
    
      | Progestin Minipill
 While somewhat less effective than combined preparations when used as 
        a regular birth control method, the progestin-only minipill may outshine 
        the former when it comes to emergency use. Not only is its efficacy thought 
        to be greater, but nausea and vomiting are significantly less common, 
        and it can be used even by women who cannot tolerate estrogen. The catch 
        is that the required dosage of levonorgestrel, 0.75 mg may be unavailable 
        in a single- or two-tablet format. In order to obtain postcoital protection, 
        a woman must ingest two doses of 20 tablets each of norgestrel 12 hours 
        apart, beginning within 72 hours of exposure. (Only half of the norgestrel 
        pill consists of levonorgestrel; hence, the necessity for 20 tablets.) 
        Faced with such an inconvenient and expensive regimen, most patients are 
        willing to overlook the gastrointestinal effects associated with the combined 
        preparations.
 | 
    
      | Copper 
        T-380 A Intrauterine Device The Copper-T IUD will prevent pregnancy up to five days following unprotected 
        intercourse. Although not suitable for all women, the device is significantly 
        more effective than either form of oral emergency contraception, reducing 
        the risk of pregnancy by 99%.
 Mechanism of action: Not firmly established, depending on the timing of insertion, may 
        interfere with sperm transport or implantation. Because the method prevents 
        implantation, an IUD may be inserted up to five days after the earliest 
        estimated date of ovulation.
 Side effects and risks are the same as those for IUD insertion at other times. 
        If left in place, it will provide continuous effective contraception for 
        up to 10 years. However, potential users should be carefully screened, 
        as insertion may not be advisable in women who have elevated risk for 
        PID or other sexually transmitted infections. Use is not recommended in 
        women who have been raped, as they may have been exposed to sexually transmitted 
        disease in the process. For women who are not at risk for STD, the health 
        risks associated with IUD use are very low.
 Contraindications: Confirmed or suspected pregnancy is a contraindication to the IUD, 
        as presence of the device may cause spontaneous abortion, septic second-trimester 
        abortion, or premature delivery.
 | 
    
      | Antiprogestins 
        RU 486 (Mifepristone) Mifepristone inhibits ovulation and blocks 
        implantation by causing a delay in endometrial maturation. It causes an 
        actual regression of the corpus luteum in 50 percent of women when given 
        in the middle or late luteal phase. Only mifepristone is effective once 
        implantation has occurred, actually interrupting an early pregnancy.
 In trials, RU 486, given as a single 600-mg dose 
        within 72 hours after unprotected intercourse, was 100% effective as an 
        emergency contraceptive. Other doses, 50 mg or 10 mg, given as a single 
        dose within five days of unprotected sex were also effective in decreasing 
        pregnancy rate by 85 %.
 Dose: 10 mg, 50 mg, 600 
        mg
 Timing of first dose after intercourse: 
        0 to 120 hours
 Reported efficacy: 85 to 100% effective
 Side effects: Less nausea and vomiting than the Yuzpe regimen. 18 % to 36 % of 
        women experienced delay of menses of more than three days. The side effects 
        were significantly related to the dose of RU 486 used.
 | 
    
      | After 72 Hours What is the patient presents for care after 72 hours have passed, and 
        the IUD is not an option? While we know that treatment efficacy does not 
        drop to zero 73 or 74 hours after exposure, there obviously is a cutoff, 
        somewhere around one week, beyond which an oral agent would be futile. 
        Prior to that point, the decision of whether or not to proceed becomes 
        a judgment call on the part of the patient and the physician. Although 
        intervention may not succeed, it might be worth a try if the patient wants 
        it, with the reassurance that no harm will be done is she becomes pregnant.
 |